NCT04586660ACTIVE_NOT_RECRUITINGanonymous

An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Sponsor

Source record

Amgen

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

XGEVA®

Indication / condition

AI-normalized

Giant Cell Tumor of Bone

Intervention

Source record

XGEVA®

Related intelligence directories

Indication directory: Giant Cell Tumor of Bone Modality directory: small molecule Target directory: XGEVA®

Source & freshness

Source record

NCT ID

NCT04586660

Original source

ClinicalTrials.gov

Source last updated

Oct 01, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04586660

Title

An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Sponsor

Amgen

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Condition raw

Giant Cell Tumor of Bone

Condition normalized

Giant Cell Tumor of Bone

Modality raw

small molecule

Modality normalized

small molecule

Target raw

XGEVA®

Target normalized

XGEVA®

Interventions

XGEVA®

Public preview

Source record

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT04586660

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE4

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 01, 2025

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04586660

Indication

Giant Cell Tumor of Bone

Modality

small molecule

Target

XGEVA®

Intervention

XGEVA®

Source record